# Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients

> **NCT03290820** · PHASE2 · UNKNOWN · sponsor: **Sun Yat-sen University** · enrollment: 184 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma

## Interventions

- **RADIATION:** Radiotherapy
- **DRUG:** Concurrent chemotherapy
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT03290820
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-01-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2017-10-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03290820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03290820, "Aspirin Improve Survival of N2-3 Nasopharyngeal Carcinoma Patients". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03290820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*